Ad hoc announcement pursuant to Art. 53 LR 2026/10/22
Galenica continues growth trajectory and confirms outlook for 2026
- Galenica increases sales by 5.7% to CHF 3,172.0 million in the first nine months of 2026.
- The pharmacy business and home care are key contributors to growth.
- Diagnostics continues to perform positively.
- Galexis successfully completes a comprehensive modernisation of its IT systems.
- Galenica confirms its outlook for the 2026 financial year.
Galenica continued its growth trajectory in the first nine months of 2026 and increased sales by 5.7% to CHF 3,172.0 million. The main drivers were the continued positive performance in the pharmacy business, strong growth in the home care sector and the integration of the Diagnostics business segment. Temporary restrictions on the product range during the ERP migration resulted in weaker growth in the wholesale business in the third quarter.
Julian Fiessinger, CFO of Galenica, sums up the sales result: “We continued our growth trajectory in the high-margin Products & Care segment in the third quarter. The good performance of our pharmacy business and the strong growth in the home care sector are particularly pleasing. Following the successful ERP switchover, we also expect to see higher growth momentum again in wholesale in the fourth quarter. We are therefore still on track to achieve our guidance.”
Pharmacy business continues to develop positively
The Pharmacies Omni-channel business segment continued its positive development, increasing net sales by 6.2% to CHF 1,134.5 million, with organic growth of 4.5%. Sustained strong demand for prescription-only medication once again proved to be a growth driver. These include, in particular, GLP-1-based weight loss products and medications for the treatment of rheumatic diseases. Taking into account the product mix (Rx and OTC products: +5.3%2, non-drugs segment in the consumer healthcare market: +1.1%3), this results in further market share gains for Galenica pharmacies.
Demand for fee-based advisory and healthcare services also continued to increase: Around 290,000 such services were provided in the first nine months (+26%), including 34,000 vaccinations.
Consumer healthcare market remains competitive
The Products & Brands business segment generated net sales of CHF 136.5 million (-7.2%), driven in particular by seasonal factors as well as adverse one-off effects in the international business. Due to the portfolio’s focus on flu and cold products, market sales of Verfora products declined by 2.4% in a challenging market environment. By comparison, the Swiss market for over-the-counter healthcare products remained flat, growing by 0.3%3 in the first nine months of 2026.
Strong growth in Home Care, continued positive performance in the Diagnostics segment
The Services & Production business segment performed positively in the first nine months of 2026, increasing net sales by 5.8% to CHF 93.6 million; excluding the impact of the closure of Bichsel’s pharmaceutical production operations, growth amounted to 10.5%. The home care business of Bichsel, Lifestage Solutions and Medifilm was once again a key driver of growth. The Diagnostics business segment also continued to develop positively, contributing CHF 91.6 million to the Galenica Group’s net sales in the first nine months of 2026.
Successful ERP migration at Galexis
Galexis reached an important milestone in its wholesale business with the successful ERP migration at the Niederbipp site. The final implementation step was completed in September and the foundations were laid for the further development of logistics services and for further increasing automation and efficiency in the wholesale business. The temporary product range restrictions associated with the switchover led to a slowdown in growth in the third quarter. Galenica expects higher growth momentum again in the fourth quarter.
The wholesale business segment generated net sales of CHF 2,441.3 million (+2.8%). In the same period, the overall pharmaceutical market grew by 3.5%2, while the physicians segment generated growth of 2.7%2, and the bricks-and-mortar pharmacy segment grew by 5.3%2. The Logistics & IT Services business segment generated net sales of CHF 58.6 million, representing a slight increase of 0.5% year on year.
2026 outlook confirmed
Galenica confirms its outlook for the 2026 financial year, with sales growth of between 5% and 7%, adjusted EBIT1 growth of between 6% and 8% and a dividend at least equal to the previous year’s level.
Net sales of the Galenica Group January – September 2026
(in million CHF) | Sept. 2026 | Sept. 2025 | Change |
|---|---|---|---|
Products & Care segment | 1,446.3 | 1,304.4 | 10.9% |
Pharmacies Omni-Channel | 1,134.5 | 1,068.0 | 6.2% |
Products & Brands | 136.5 | 147.1 | -7.2% |
Services & Production | 93.6 | 88.4 | 5.8% |
Diagnostics | 91.6 | 7.9 | |
Logistics & IT segment | 2,498.0 | 2,432.2 | 2.7% |
Wholesale | 2,441.3 | 2,375.9 | 2.8% |
Logistics & IT Services | 58.6 | 58.4 | 0.5% |
Corporate and eliminations | -772.4 | -736.9 | |
Galenica Group | 3,172.0 | 2,999.7 | 5.7% |
__________
1 See definition in the chapter “Alternative performance measures” in the Annual Report 2025.
2 IQVIA, Pharmaceutical Market Switzerland, YTD September 2026.
3 IQVIA, Consumer Health Market Switzerland, YTD September 2026.
Additional information on sales figures, explanations of the approach to sales presentation and further information can be found in our sales presentation. |
You might also be interested in this
Five football pitches full of medication – and one system for emergencies
Millions of packs of medicines are stored in Burgdorf. Some of them are intended for the moment when the market can no longer guarantee supply. How this compulsory stock works and is drawn upon, why it is far from being a dusty emergency reserve, and what role the Galenica network company Alloga plays in supplying Switzerland.
A new gem joins the network: Galenica acquires Bären Apotheke am Zytglogge
The long-established Bären Apotheke am Zytglogge has been part of Bern’s cityscape for generations. Since 1 September 2026, it has been part of the Galenica network and continues to operate under the name “Bären Vita Zytglogge” with a new concept. This preserves a piece of Bern’s history while opening up new prospects for its future.
Creating New Spaces in Harmony with Our Culture
The world of work is constantly evolving, and Galenica is evolving with it. As part of our transformation, we are actively shaping the future. This is reflected not only in the way we collaborate, but also in the environments in which we work.
Coordinated basic care: From pilot projects to system solutions
Collaboration between different healthcare providers is already being tested in numerous pilot projects. One recent example is the Baselland supply model, which also involves participation from pharmacies in the Galenica network. The task going forward is to develop these approaches systematically and translate them into sustainable, broad-based system solutions. Daniele Madonna, Chief Pharmacies Category Management & Health Services, called for this step at this year’s Healthcare Professionals Initiative on 5 June 2026.
Sun Store Renens: First pharmacy in Western Switzerland to introduce the new concept
With the redesigned Sun Store pharmacy in Renens (VD), the first pharmacy in Western Switzerland is opening with a completely new concept. It places a strong focus on personalised advice, healthcare services and the overall customer experience. The aim is to further improve people’s access to low-threshold primary care services.